Literature DB >> 3660288

Importance of airflow obstruction after thoracoplasty.

M S Phillips1, M R Miller, W J Kinnear, S E Gough, J M Shneerson.   

Abstract

Thirty six patients previously treated for pulmonary tuberculosis by thoracoplasty were studied to determine the prevalence and effect of airflow obstruction. The mean (SD) FEV1 was 1.3 (0.65) 1 and the mean forced expiratory ratio (FER) 64% (12%). FEV1 was less than predicted in every patient whereas FER was less than predicted in 30, being below the lower 98th percentile in 15 (42%). In the 18 patients who complained of breathlessness the means of the standardised residuals (SR) for FEV1, peak expiratory flow (PEF), and FER were significantly lower and that for residual volume/total lung capacity (RV/TLC) significantly higher than those for the 18 patients who were not breathless (all p less than 0.0001). There was no difference in the smoking history of the two groups. Only three of the 23 patients in whom reversibility of airflow obstruction was assessed showed a greater than 25% increase in PEF. None showed an increase in FEV1 of greater than 15%. The 18 who were breathless had significantly lower values of arterial oxygen tension (PaO2) and higher values of arterial carbon dioxide tension (PaCO2) (p less than 0.0001). Thirteen of these patients were in chronic respiratory failure (PaO2 less than 8.0 kPa or PaCO2 greater than 5.9 kPa, or both) compared with only one of the 18 who were not breathless. The indices correlating best with PaO2 and PaCO2 were SR FEV1 and SR PEF respectively. SR FEV1 accounted for 34% of the variance in PaO2 and SR PEF for 29% of the variance in PaCO2. Airflow obstruction has been found to be common in patients with a thoracoplasty and to be associated with hypoxia and hypercapnia.

Entities:  

Mesh:

Year:  1987        PMID: 3660288      PMCID: PMC460754          DOI: 10.1136/thx.42.5.348

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

1.  Chronic bronchitis as an etiologic factor in obstructive emphysema; preliminary report.

Authors:  E A GAENSLER; I LINDGREN
Journal:  Am Rev Respir Dis       Date:  1959-07

2.  The role of pulmonary insufficiency in mortality and invalidism following surgery for pulmonary tuberculosis.

Authors:  E A GAENSLER; D W CUGELL; I LINDGREN; J M VERSTRAETEN; S S SMITH; J W STRIEDER
Journal:  J Thorac Surg       Date:  1955-02

3.  Comparative study of pulmonary function loss: thoracoplasty versus small resection in surgery of tuberculosis.

Authors:  F B LANDIS; W WEISEL
Journal:  J Thorac Surg       Date:  1954-04

4.  Hemodynamics: studies on a group of patients who developed cor pulmonale following thoracoplasty.

Authors:  H A ZIMMERMAN
Journal:  J Thorac Surg       Date:  1951-07

5.  Scoliosis after thoracoplasty.

Authors:  R D Loynes
Journal:  J Bone Joint Surg Br       Date:  1972-08

6.  Diaphragmatic movement and spirometric volume in patients with one functioning lung.

Authors:  B N Hauge
Journal:  Scand J Respir Dis       Date:  1971

7.  Maximal respiratory pressures: normal values and relationship to age and sex.

Authors:  L F Black; R E Hyatt
Journal:  Am Rev Respir Dis       Date:  1969-05

Review 8.  Assisted ventilation at home: is it worth considering?

Authors:  W J Kinnear; J M Shneerson
Journal:  Br J Dis Chest       Date:  1985-10

9.  Respiratory failure after thoracoplasty: treatment by intermittent negative-pressure ventilation.

Authors:  E H Sawicka; M A Branthwaite; G T Spencer
Journal:  Thorax       Date:  1983-06       Impact factor: 9.139

10.  Synthetic and fermentation type chloramphenicol (chloromycetin) in typhoid fever; prevention of relapses by adequate treatment.

Authors:  J E SMADEL; C A BAILEY; R LEWTHWAITE
Journal:  Ann Intern Med       Date:  1950-07       Impact factor: 25.391

View more
  1 in total

1.  Long term non-invasive domiciliary assisted ventilation for respiratory failure following thoracoplasty.

Authors:  M Jackson; I Smith; M King; J Shneerson
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.